Parkinson’s Disease is a progressive neurological disorder that will eventually lead to a late or end‑stage with severe symptoms and complex care requirements. The phase needs to be addressed for ...
Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class ...
Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback